PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Intertrust acts as administrator on USD300 million European life sciences fund

Intertrust NV has been appointed by Medicxi to provide fund administration, accounting and compliance services to a USD300 million growth fund targeting late stage European life sciences companies.

Medicxi, which has offices in London, Geneva and Jersey, is one of the leading independent European life sciences investment firms. The new fund, Medicxi Growth I will fill a clear late-stage funding gap in Europe by offering financial support to life sciences entrepreneurs.
 
Paul Lawrence, Global Head of Funds at Intertrust, says: “We have enjoyed a solid relationship with Medicxi, including a successful partnership with Elian prior to its acquisition by Intertrust in 2016. We have a proven track record in providing quality client service and we look forward to continuing to work with Medicxi on this new fund. It’s good to see a fund of this nature being raised in the life sciences space and the positive social contribution they deliver.
 
“The high level of expertise and experience held within our funds team means we continue to broaden and strengthen our relationships with fund managers.”

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured